Pacira BioSciences to Present at Two Healthcare Conferences in November
November 08, 2022 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare...
Pacira BioSciences Reports Third Quarter 2022 Financial Results
November 03, 2022 08:00 ET
|
Pacira BioSciences
-- Third quarter revenue of $167 million, increased 31% over prior year ---- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc....
Pacira to Report Third Quarter 2022 Financial Results on Thursday November 3, 2022
October 20, 2022 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on...
Pacira BioSciences Reports Preliminary Third Quarter 2022 Revenue of $167.5 Million
October 13, 2022 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today...
Sevāredent Sourcing Solutions and Pacira BioSciences Collaborate to Provide Expanded Access to EXPAREL for Patients Undergoing Oral and Maxillofacial Procedures
September 27, 2022 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Sevāredent Sourcing Solutions, a Group Purchasing Organization (GPO) that creates a competitive advantage for like-minded dental organizations through...
Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy
September 21, 2022 08:00 ET
|
Pacira BioSciences
-- Second Phase 3 study achieves primary and key secondary endpoints; safely demonstrating statistically significant reductions in postsurgical pain and opioid consumption through 96 hours -- --...
Pacira Receives Positive CHMP Opinion for EXPAREL® for the Treatment of Postsurgical Pain in Children Aged 6 or Older
September 20, 2022 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the leading global provider of non-opioid pain management options, announced that the European Medicines...
Pacira BioSciences Reports Preliminary Net Product Sales of $59.1 Million for August 2022
September 13, 2022 08:00 ET
|
Pacira BioSciences
-- EXPAREL average daily sales for August 2022 were 108 percent of August 2021 – -- More than 11 million patients have received EXPAREL since launch -- TAMPA, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE)...
Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty
September 07, 2022 07:00 ET
|
Pacira BioSciences
TAMPA, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today...
Pacira BioSciences Reports Preliminary Net Product Sales of $50.2 Million for July 2022
August 10, 2022 08:00 ET
|
Pacira BioSciences
-- EXPAREL average daily sales for July 2022 were 105 percent of July 2021 -- TAMPA, Fla., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its...